GI.1/GII.4 (15/15)
NOR-202
Phase 2 mab completed
Quick answer
GI.1/GII.4 (15/15) for Norovirus is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Norovirus
- Phase
- Phase 2
- Modality
- mab
- Status
- completed